First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation by Ramita Dewan et al.
CASE REPORT Open Access
First insight into the somatic mutation
burden of neurofibromatosis type 2-
associated grade I and grade II
meningiomas: a case report comprehensive
genomic study of two cranial meningiomas
with vastly different clinical presentation
Ramita Dewan1†, Alexander Pemov2†, Amalia S. Dutra3, Evgenia D. Pak3, Nancy A. Edwards1,
Abhik Ray-Chaudhury1, Nancy F. Hansen4, Settara C. Chandrasekharappa4, James C. Mullikin4,5, Ashok R. Asthagiri6,
NISC Comparative Sequencing Program, John D. Heiss1, Douglas R. Stewart2 and Anand V. Germanwala7,8*
Abstract
Background: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant nervous system tumor predisposition
disorder caused by constitutive inactivation of one of the two copies of NF2. Meningiomas affect about one half of
NF2 patients, and are associated with a higher disease burden. Currently, the somatic mutation landscape in NF2-
associated meningiomas remains largely unexamined.
Case presentation: Here, we present an in-depth genomic study of benign and atypical meningiomas, both from
a single NF2 patient. While the grade I tumor was asymptomatic, the grade II tumor exhibited an unusually high
growth rate: expanding to 335 times its initial volume within one year. The genomes of both tumors were
examined by whole-exome sequencing (WES) complemented with spectral karyotyping (SKY) and SNP-array copy-
number analyses. To better understand the clonal composition of the atypical meningioma, the tumor was divided
in four sections and each section was investigated independently. Both tumors had second copy inactivation of
NF2, confirming the central role of the gene in meningioma formation. The genome of the benign tumor closely
resembled that of a normal diploid cell and had only one other deleterious mutation (EPHB3). In contrast, the
chromosomal architecture of the grade II tumor was highly re-arranged, yet uniform among all analyzed fragments,
implying that this large and fast growing tumor was composed of relatively few clones. Besides multiple gains and
losses, the grade II meningioma harbored numerous chromosomal translocations. WES analysis of the atypical
tumor identified deleterious mutations in two genes: ADAMTSL3 and CAPN5 in all fragments, indicating that the
mutations were present in the cell undergoing fast clonal expansion
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Conclusions: This is the first WES study of NF2-associated meningiomas. Besides second NF2 copy inactivation, we
found low somatic burden in both tumors and high level of genomic instability in the atypical meningioma.
Genomic instability resulting in altered gene dosage and compromised structural integrity of multiple genes may
be the primary reason of the high growth rate for the grade II tumor. Further study of ADAMTSL3 and CAPN5 may
lead to elucidation of their molecular implications in meningioma pathogenesis.
Keywords: Whole exome sequencing, Single nucleotide polymorphism, Spectral karyotyping, NF2 gene, Somatic
mutation, Case report
Background
Neurofibromatosis type 2 (NF2) is an autosomal domin-
ant tumor syndrome characterized by the growth of
multiple neoplasms within the central nervous system.
Although bilateral vestibular schwannomas are the hall-
mark of NF2, meningiomas are the second most fre-
quent intracranial tumor, and occur in about 52% of
NF2 patients [1, 2]. Benign meningiomas (WHO grade I)
feature a 5-year tumor recurrence rate of 5% as compared
to 50–80% for anaplastic meningiomas (grade III),
highlighting the importance of elucidating the molecular
mechanisms which contribute to tumor progression [3].
The most common genetic mutation in meningiomas
is NF2 inactivation, which is observed not only in NF2-
associated tumors, but also in 47 to 72% of sporadic
meningiomas, and is thus considered an integral step for
meningioma tumor initiation [4–6]. Recent studies util-
izing high throughput whole-exome and whole-genome
sequencing have identified two distinct subtypes of spor-
adic meningiomas: tumors with or without an inacti-
vated NF2 gene [7, 8]. Sporadic meningiomas with
disrupted NF2 tend to display greater genomic instability
(including several cases of chromothripsis) and higher
grades than non-NF2 meningiomas. Non-NF2 tumors
have been shown to contain recurrent oncogenic muta-
tions in AKT1, KLF4, TRAF7 and SMO, indicating the
alternate involvement of the PI3K-AKT and Hedgehog
signaling pathways.
NF2-associated meningiomas are rarer than their spor-
adic counterparts and far fewer studies have investigated
the genetics underlying their initiation and progression.
Two case series evaluated meningiomas from NF2
patients only for the allelic imbalances most commonly
observed in sporadic meningiomas, and confirmed fre-
quent somatic inactivation of the NF2 gene, as well as
losses of chromosome arms 1p, 6q, 9p, 10q, 14q and 18q
[9, 10]. A more recent study used single nucleotide poly-
morphism array analysis to report increased chromo-
somal instability with increasing grade in NF2-associated
meningiomas [11].
Here, we present an in-depth genomic study of grade I
and grade II meningiomas that resided in close proximity
in the brain of an NF2 patient. The tumors contained the
same NF2 germline mutation and similar somatic hits af-
fecting the normal remaining copy of the gene, yet differed
drastically in genomic architecture and growth rate. The
tumors were investigated using whole-exome sequencing





A 35-year-old woman was enrolled in the Institutional
Review Board (IRB)-approved NF2 natural history study
(NIH#08-N-0044) at the National Institute of Neurologic
Disease and Stroke (NINDS). Prior MR imaging con-
firmed the NF2 Manchester diagnostic criteria of bilat-
eral vestibular schwannoma in addition to numerous
other significant findings: intracranial schwannomas in-
volving cranial nerves V, VII, and VIII, intracranial men-
ingiomas, cervical ependymomas, schwannomas along
the cauda equina, and cervicothoracic meningiomas.
In preparation for surgery, the patient underwent
frameless stereotactic navigation imaging on a 1.5 Tesla
MRI scanner with and without gadolinium. 1-mm axial
images were obtained with sagittal and coronal recon-
struction. Image guidance registration was performed in-
traoperatively using facial registration.
Surgical resection
A single image-guided right frontal craniotomy was used
to resect an anterior grade II meningioma, in four
discrete sections, and a posterior grade I meningioma.
The two meningiomas were separated by an intervening
section of normal brain, and were resected through a
single image-guided right frontal craniotomy. The anter-
ior grade II meningioma was noted to be soft and was
removed in four anatomically discrete sections with al-
ternating steps of circumferential dissection and suction.
The posterior grade I meningioma was noted to be firm
and was removed en bloc.
Histopathology analysis
Tumor specimens were fixed in 10% buffered formalin
immediately after removal, processed overnight, and
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subsequently embedded in paraffin. Five μm-thick sec-
tions were obtained from the paraffin blocks, and
stained using the standard hematoxylin and eosin
method.
DNA extraction
Frozen tumor tissue was processed with Proteinase K,
and DNA extraction was completed using the phenol:-
chloroform procedure. Frozen tumor tissue was minced
with a scalpel, washed once in PBS, pH 7.4, and incu-
bated in a solution containing 100 mM TrisHCl, pH 8.0,
5 mM EDTA, 0.5% SDS and 200 μg/mL Proteinase K
(Invitrogen, Grand Island, NY) at 55 °C for 2–3 h or at
37 °C overnight. DNA was extracted by the phenol:-
chloroform procedure and precipitated with ice cold iso-
propanol. DNA pellets were air dried, re-suspended in
10 mM TrisHCl, pH 7.4 and 0.1 mM EDTA, aliquoted
and stored at −20 °C.
Whole-exome sequencing (WES) of tumor and normal DNA
Capture of the coding portion (exome) of genomic DNA
and library preparation for next generation sequencing
was done using Roche NimbleGen (Madison, WI)
SeqCap EZ Exome + UTR library (64 Mb of coding
exons and miRNA regions plus 32 Mb
untranslated regions (UTR)) according to the manu-
facturer’s instructions. As an input, 1 μg of tumor and
matching normal genomic DNA was used. Sequencing
was completed on the Illumina HiSeq 2500 system
(Illumina, San Diego, CA, USA). Among the six exomes
sequenced, the average breadth of coverage was 89%
(range 88–90%), and the average depth of coverage was
66X (range 54X-78X).
Raw sequencing data was further processed using an
analytical pipeline that included ELAND (Illumina, Inc.)
for initial alignment to the reference human genome
(GRCh37); Novoalign, v.2.08.02 [12] for local re-
alignment; bam2mpg for genotype calling and calcula-
tion of the quality score Most Probable Genotype
(MPG) [13] and ANNOVAR for functional annotation of
genetic variants [14, 15]. The resulting data was format-
ted in VarSifter [16] format for further filtering.
Filtering consisted of removing all non-coding variants
and nucleotides whose genotypes were identical in both
the tumor and corresponding germline DNA, whose
quality score (Most Probable Genotype, MPG) was less
than 10 in either tumor or normal DNA, and whose ra-
tio of quality score to depth of coverage was below 0.5
in germline DNA and below 0.4 in tumor DNA. All
common variants (variants with minor allele frequency
above 0.03 in ClinSeq and 1000 Genomes databases)
were also removed. The resulting set was annotated with
PolyPhen, SIFT and CADD tools to identify pathogenic
mutations.
Sanger validation of mutations identified by WES
PCR primers were designed using Primer3 (v. 0.4.0) on-
line software [17]. PCR amplification was conducted
using a 20 μL reaction mixture containing 20–50 ng of
genomic DNA, 1x reaction buffer, 1.5 mM MgCl2, 4
dNTPs at 250 μM each, 10 pmole each of forward and
reverse primers, and 2 units of ThermoFisher Scientific
Taq DNA polymerase (Waltham, MA). PCR products
were analyzed on Agilent 2100 BioAnalyzer (Santa Clara,
CA) and sent for Sanger sequencing to ACGT, Inc.
(Wheeling, IL). Sequencing was done on ABI 3730 DNA
Analyzer, the data was processed with GeneMapper v.3.7
software (ThermoFisher Scientific), and the phred
quality score for sequenced nucleotides was visualized
using CodonCode Aligner v.6.0.2 (CodonCode Corp.,
Centerville, MA). Sequencing reaction tracks were visu-
alized using FinchTV v.1.5.0 (Geospiza, Inc., Seattle,
WA) and CodonCode Aligner software.
Sanger sequencing of NF2
Sanger sequencing of NF2 was conducted by Prevention
Genetics (Marshfield, WI), a CLIA-certified DNA testing
lab. PCR was used to amplify all NF2 coding exons, as
well as ~20 bp flanking intronic or other non-coding se-
quence. Sequencing was performed separately in both
the forward and reverse directions and all differences
from the reference sequence were reported.
SNP-array analysis
SNP genotyping was performed using HumanOmni
ExpressExome-8v1.2 Illumina BeadChip arrays (Illumina,
San Diego, CA) per the manufacturer’s instructions. The
arrays were read using the iScan platform (Illumina),
and visualized with GenomeStudio v.2011.1 software
(Illumina). The call rate for all the DNA samples was
>99%. Genomic coordinates are per hg19.
Copy-number variation analysis
Copy-number variation (CNV) analysis of all tumor
samples was performed using Nexus Copy Number soft-
ware v.6.1 (BioDiscovery, Inc., Hawthorne, CA). “Allelic
imbalance” refers to a locus with B-allele frequency
classes other than 0, 0.5 or 1. Allele-Specific Copy num-
ber Analysis of Tumors (ASCAT) (v2.1) analysis of the
data was performed as described by Van Loo and co-
authors [18].
Spectral karyotyping (SKY)
Metaphase slide preparations were made from cultured
meningioma primary cell cultures established from the
grade II meningioma and hybridized with commercially
available SKY probe set (Applied Spectral Imaging Inc.,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. Mitotic arrest with colcemid (0.015 μg/mL, 2–4 h)
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(GIBCO, Gaithersburg, MD) was followed by hypotonic
treatment (75 mM KCl, 20 min, 37 °C) and fixation in
methanol–acetic acid mixture (3:1).
Results
Clinical presentation
The patient, over 12 months of enrollment, noted pro-
gressively worsening right frontal headaches. The patient
had a family history of NF2 and was deaf from bilateral
vestibular schwannomas that were successfully treated in
the past with radiosurgery. Her neurological exam was
notable only for bilateral deafness. Over the 12-month
period, the patient was noted to have significant radio-
graphic progression of a right anterior frontal meningi-
oma, increasing to 335 times its original volume, while
other brain and spine tumors remained relatively stable
(Fig. 1). Due to the tumor’s symptomatic radiographic
progression, surgical resection was offered. Consent to
remove an adjacent, stable posterior frontal tumor was
also obtained in the setting that it was accessible for re-
section without posing additional risk. The patient had
an unremarkable hospital course and post-operative im-
aging confirmed gross total resection of both lesions. At
six weeks follow-up, the patient noted significant im-
provement in her headaches.
Histopathological analysis of the tumors
Histological analysis of the anterior tumor revealed a
grade II meningioma with increased cellularity, nuclear
pleomorphism, cells with prominent nucleoli and areas
of patternless growth. Increased proliferation index as
evidenced by immunostain for MIB-1 antigen was also
observed. Pathology of the posterior specimen revealed a
grade I meningioma consisting of monomorphic cells
having ovoid to elongated nuclei, multiple cellular
whorls, scattered psammoma bodies and rare mitotic fig-
ures (Fig. 2).
Germline and somatic mutations in the NF2 gene
Sequencing of exons and small flanking intronic regions
of the NF2 gene from peripheral white blood cell DNA
(germline) identified a constitutive mutation in the in-
tronic region, two nucleotides upstream of the 5′-end of
exon 13: c.1341-2A > C. This mutation likely disrupts
the acceptor site of intron 12, thus affecting RNA spli-
cing, and has been previously reported as pathogenic
(Human Gene Mutation Database, CS115647) by Ellis
and co-authors [19]. It has not been previously anno-
tated in the ExAC (mean coverage 15x), 1000 Genomes,
or ESP datasets [20].
The mutation was identified in the patient’s peripheral
white blood cell DNA by a CLIA-certified genetic testing
lab (Prevention Genetics, Marshfield, WI, data not
shown). We performed secondary confirmation using
PCR amplification followed by Sanger sequencing of the
DNA fragment containing the mutant base. Both
Prevention Genetics (PG) and our analyses of germline
DNA revealed the presence of a mutant base C in the
sequence (Fig. 3). Examination of phred quality scores
for the mutant base and several surrounding nucleotides
Fig. 1 MRI and growth rate analysis of the grade I and grade II meningiomas. a MRI images of the patient’s tumors at the start of the study, and
6 and 12 month time points. The slowly and rapidly growing tumors are indicated with white and red arrows, respectively. Numbers 1 through 5
on the bottom image show the tumor samples taken for genomic analysis: 1- grade I (slowly growing) meningioma, and 2 through 5 - regions of
the grade II (rapidly growing) meningioma. b Growth rate volumetric analysis of the tumors shown in a, with the grade II tumor displaying
exponential growth
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revealed lower values in the patient’s germline DNA
compared to the normal control (Additional file 1). This
was in agreement with visual evaluation of the chro-
matogram peaks: the presence of C signal in addition to
A signal at this nucleotide position made an unambigu-
ous call less certain, resulting in a lower quality score
(Fig. 3 and Additional file 1).
We noticed that the mutant signal (C) was weaker
than that of the reference allele (A) (Fig. 3, see
“Germline” panel). A similar A-to-C signal ratio was ob-
served in both the plus and minus strand DNA se-
quences in both PG and our analyses (data in Fig. 3 is
shown for the plus strand only). A-to-C substitution in
the sequence 5′-GG[A]GGGCC-3′ converts it to a GC-
rich 8 nucleotide-long stretch 5′-GG[C]GGGCC-3′.
Such sequences can be more difficult to analyze due to
the secondary DNA structure, which may explain the
decreased mutant base C signal.
Copy number analysis of the tumors revealed that the
grade I meningioma contained loss of entire chromo-
some 22, and all fragments of the grade II meningioma
harbored loss of chromosome 22q (Fig. 4). Thus, loss of
heterozygosity (LOH) was the likely mechanism of som-
atic NF2 inactivation. PCR amplification followed by
Sanger-sequencing of the region surrounding c.1341-
2A > C substitution in all tumor samples revealed mostly
homozygous mutant genotype (C/C), confirming loss of
the remaining wild-type copy of the NF2 gene. One can
observe a weak reference allele A signal in the tumor
sequencing chromatograms, due to the presence of
20–30% of non-tumor stromal cells that still contain the
reference allele (Fig. 3, bottom four panels, “Grade I’,
“Grade II-1”-“Grade II-4”, green peaks). These observa-
tions were also confirmed by lower phred scores of the
mutant nucleotide in all tumor samples compared to nor-
mal DNA control (Additional file 1).
Copy-number SNP-array analysis
We investigated copy-number variation (CNV) in the
grade I and grade II meningiomas on Illumina SNP-
arrays, followed by Nexus CNV software analysis (Fig. 5).
Besides LOH of entire chromosome 22, the grade I
tumor contained only a single 22 kilobase deletion on
chromosome 8p23.2, in an intronic region of CSMD1. In
contrast, we observed multiple gains and losses, ranging
from a few kilobases to 100 megabases in eleven differ-
ent chromosomes in the grade II tumor (Table 1 and
Additional file 2). The deleted and amplified regions in
the grade II tumor harbor more than 3000 genes
(Additional file 3), 54 of which are known cancer genes
(Additional file 4).
Spectral karyotyping (SKY) of grade II meningioma cells
SNP-array analysis, while providing data on copy-
number variation in the genome, does not permit detec-
tion of structural chromosomal rearrangements such as
inversions and translocations. To address this, we used
primary cell cultures established from the grade II
meningioma for SKY analysis. Viable cultures from the
grade II-2, grade II-3 and grade II-4 tumor fragments
Fig. 2 Histological appearance of benign and atypical meningioma. a Histological analysis of the posterior specimen revealed a grade I
meningioma with typical whorl formations (bar 100 μm) and b psammoma bodies (bar 100 μm). c The anterior tumor revealed a grade II
meningioma with increased cellularity, nuclear pleomorphism, and prominent nucleoli as indicated by H&E (bar 50 μm) and d an increased
proliferation index by MIB-1 labeling (bar 50 μm)
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contained cells of normal ploidy, and both unaffected
cells (20–40%) and cells with multiple chromosomal
translocations (Table 2). Within each culture, approxi-
mately half of the translocations were recurrent. In one
culture (grade II-2), we observed highly abnormal cells
with chromosomes that appeared “shattered” or broken
into multiple fragments.
Whole-exome sequencing (WES) of tumors and Sanger
verification of mutations
After WES data processing and filtering, we identified
two potentially damaging somatic mutations in the grade I
meningioma, and nine somatic mutations in the four frag-
ments of the grade II meningioma (Additional file 5). Of
the nine mutations in the grade II meningioma, two were
found in all four fragments.
Of the two mutations in the grade I meningioma, one
(EPHB3) mutation was verified by Sanger sequencing,
and of the nine mutations in the grade II tumor, two
(CAPN5 and ADAMTSL3) were verified by Sanger se-
quencing. Importantly, the mutations in CAPN5 and
ADAMTSL3 were detected by WES in all four fragments
of grade II tumor and were verified by Sanger in all four
fragments as well, suggesting that these mutations
were likely present in the cell undergoing fast clonal
expansion.
Discussion
To our knowledge, this is the first whole-exome sequen-
cing study of NF2-associated grade I and grade II men-
ingiomas. Besides chromosome 22 loss, the genome of
the grade I meningioma closely resembled that of a
Fig. 3 Sanger analysis of grade I and grade II tumors. Sequencing tracks of the genomic region surrounding the splice site mutation (Exon 13;
c.1341-2A > C) upstream of exon 13 in the NF2 gene in normal control DNA, and germline and tumor DNA of the NF2 patient. “Grade II-1”
through “Grade II-4” labels denote the four fragments of the grade II meningioma analyzed in this study. Arrows point at the mutant nucleotide,
which was heterozygous in germline and all tumor fragments. The relative font size for the alleles in each sample reflects the difference in signal
strength for A and C nucleotides at the site of the mutation
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normal diploid cell, while the genome of the grade II
tumor contained several chromosomal rearrangements
previously observed in meningiomas, including losses in
1p, 2p, 2q, 3p, 3q, 6q, 12p, 14q, 18q, Xp, gain in 1q
[21–25], and multiple translocations. Our observations
confirm previous findings that inactivation of NF2 is
likely to be the primary step in NF2-associated men-
ingioma formation [26]. In addition, we show that
both benign and atypical tumors had a low somatic
mutation burden. Although limited to a single patient,
this data permits speculation that tumor progression
to a higher grade likely occurs through multiple
chromosomal gains, losses and translocations and to a
lesser extent from the accumulation of point muta-
tions and small indels.
Chromosomal translocations leading to the disruption
of tumor suppressors or activation of proto-oncogenes
are common in many neoplasms [27, 28]. Limited evi-
dence suggests that chromosomal translocations may
also be present in meningiomas [29] and systematic
studies addressing this mechanism of tumorigenesis in
meningiomas are emerging. We observed numerous
Fig. 4 Somatic inactivation of NF2 via chromosome 22 deletion in grade I and grade II meningiomas. SNP-array analysis of grade I (top panel)
and grade II (middle panel) meningiomas and normal (germline) DNA (bottom panel). Each panel consists of two plots: B-allele frequency (top)
and intensity (bottom). Cytoband map of chromosome 22 is shown on the bottom of the figure. The arrows show the start of the deletion region
in the grade II meningioma. Data for only one of the four fragments of grade II tumor is shown, since the data for the remaining three is essentially
the same
Fig. 5 Genomic distribution of CNVs in grade I and four fragments of grade II meningiomas. Chromosomal deletions and duplications in
individual samples (lower panel) and as aggregation of all samples (upper panel) are shown as red and blue bars, respectively. Regions of allelic
imbalance are shown in purple. Individual chromosomes, 1 through 22 and X, are shown as alternating light blue and white columns. The height
of the red and blue bars in the upper panel reflects the number of samples the CNV is detected in. The percent scale is shown on the left of the
upper panel
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chromosomal translocations (both balanced and unbal-
anced) as well as one case of highly irregular, shattered
chromosomes. Interestingly, similar to the observation
made by Brastianos et al. [7], close examination of SNP-
array plots of chromosome 1 in the tumor revealed dele-
tion of the 5′-half of the NEGR1 gene (not shown).
These findings suggest that structural aberrations might
be more frequent than previously believed in NF2-driven
familial and sporadic meningiomas, and could represent
one of the mechanisms of genetic instability and routes
of tumor progression to higher grades.
By analyzing the genomic architecture and somatic
mutations in multiple fragments of the grade II tumor,
we gained insight into the clonal evolution of this fast
growing neoplasm. We observed not only a remarkably
uniform pattern of chromosomal gains and losses, but
also the consistent presence of the only two potentially
pathogenic mutations, in ADAMTSL3 and CAPN5, in all
four fragments. These findings indicate that the aberra-
tions were likely present in the initial cell undergoing
fast clonal expansion, and that any of these aberrations/
mutations could impact tumor progression and acceler-
ate growth rate.
Germline mutations in CAPN5 (Calpain 5), which
encodes a calcium-dependent endopeptidase, have been
associated with neovascular inflammatory vitreoretino-
pathy [30]. Though the role of the protein in neoplastic
transformation is unclear, a recent study reported associ-
ation of CAPN5 with promyelocytic leukemia nuclear
bodies, which are involved in transcriptional regulation,
cell differentiation, apoptosis, and cell senescence [31].
The protein encoded by ADAMTSL3 (A Disintegrin And
Metalloproteinase with TromboSpondin Like 3) is in-
volved with extracellular matrix function and to cell–
matrix interactions, and is frequently mutated and
under-expressed in colorectal cancer [32]. The gene be-
longs to a large family of proteins associated with micro-
fibrils in the extracellular matrix, thus mediating
sequestration of the TGFB superfamily of proteins and
affecting wide array of cellular functions such as adhe-
sion, migration, proliferation and angiogenesis [33, 34].
The majority of meningiomas are benign and asymp-
tomatic tumors that require little or no treatment [35, 36].
However, a subset of tumors becomes more clinically ag-
gressive as they evolve toward atypical and anaplastic
stages, causing increased morbidity and mortality. Re-
markably, the tumors we investigated had the same NF2
germline mutation, the same genetic background, similar
chromosome 22 LOH and were residing within a few
Table 1 Grade II meningioma chromosomal aberrations
identified by SNP-array analysis
Chromosome Mutation Location Previously reported?
1 Loss p36.33 to p34.2 Yes
Loss p33 to p31.3 Yes
Gain p31.3 to p31.1 No
Loss p31.1 Yes
Loss p31.1 to p22.3 Yes
Loss p22.1 to p13.2 Yes
Gain q21.2 to q21.3 Yes
Gain q21.3 to q42.13 Yes
2 Loss p23.2 Yes
Loss q22.1 Yes
3 Loss p14.2 Yes
Gain p14.2 No
Loss q26.31 Yes
6 Loss q12 Yes
Loss q13-q27 Yes
7 Gain q11.21 No
11 Loss p15.5 to p15.4 No
12 Loss p13.33 to p11.21 Yes
14 Loss q31.1 Yes
18 Loss q23 Yes
22 Loss q11.23-q13.33 Yes
X Loss p21.1 Yes
Table 2 Chromosomal translocations identified by SKY analysis








Grade II-3 20% 30% 50% 0%
46, XX, t(11;8) 46, XX, t(8;8), t(11;12)









Percent of normal metaphases and metaphases containing chromosomal
translocations (abnormal) is shown in the top row for each meningioma
grade II primary tissue culture analyzed (Grade II-2, II-3 and II-4, note that
culture from fragment II-1 could not be established). Abnormal metaphases
were further divided into recurrent or non-recurrent. Fragment 2 of the tumor
(Grade II-2) also contained 20% of cells with highly fragmented,
shattered chromosomes
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millimeters from one another in the patient’s brain, yet
one remained as a slowly growing asymptomatic grade I
meningioma and the other evolved into a fast growing
grade II tumor. This observation underscores the import-
ance of stochastic factors in meningioma progression,
which are still poorly understood.
Conclusions
We performed an in-depth genomic study of NF2-
associated benign and atypical meningiomas. Both tu-
mors had inactivated second copies of NF2 and a low
burden of somatic mutations. However, unlike the be-
nign tumor, the atypical meningioma presented with
widespread genomic aberrations, implying that chromo-
somal instability may be a key driving force in tumor
progression. In addition, we identified two candidate
driver genes, CAPN5 and ADAMTSL3, which could
contribute to the elevated growth rate of the grade II
meningioma. Future efforts should be focused on under-
standing the mechanistic links between NF2 deficiency
and genomic instability.
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